Lascco

History

2015: Clinical trials of CALO2 (Combioxin) in Europe

In 2015 the authorities of a number of the European countries (Belgium, Great Britain, France) granted permission for carrying out clinical trials of CALO2. For the testing which is taking place a product since the beginning of 2016 at which more than 10 hospitals participate it was renamed into Combioxin and it is transferred in backs-off the company of the same name. As a disease profile for tests the acute pneumonia at which death rate exceeds 30% is defined, and its activators are pneumococci and staphylococcus were the basic pathogens steady against antibiotics, during creation of CALO2.

2011: CALO2

The transfer of opening perfect in 2011 researchers of the University of Bern became the following project for family business of Lajaunias. They synthesized the substance called CALO2, consisting of the lipidic vesicles (bubbles of fat of midget amount) similar to containers which use for transportation of powerful toxins in targetny antineoplastic therapy. Specific CALO2 properties, allow to collect on themselves toxins which make pathogenic bacteria, preventing damage of cages of an organism. CALO2 lipids, being neutral for intestinal flora, remove collected toxins in "the natural way", without attacking bacteria. Means is effective addition of therapy against 8 of 12 most dangerous pathogens steady against antibiotics, determined by World Health Organization (WHO, headquarters in Geneva, Switzerland) as global threat. Lack of effective remedies of protection from which can lead to "mass return" of such diseases as tuberculosis and to many other.

Opening of CALO2 helps to fight against the phenomenon of emergence of strains of the pathogens steady against antibiotics of a broad spectrum (penicillin derivatives) to which treatment apply narrowly allocated funds which are in passing oppressing intestinal flora and also strains steady against all known antibiotics.

2008: Means of diagnosis of sepsis at seriously wounded of patients

In 2008, together with another Swiss Abionic startup company (since 2010 Abionic SA, municipality of Épalinges the Canton of Vaud) – the developer of nanotechnology rapid tests of different types of diseases, Lascco company, on the basis of researches of surgical department of hospital at the university of Zurich, was developed a method of express diagnostics of septic complications at patients with serious wounds. In department the natural biomarker of sepsis — specific protein which caption very quickly (within several minutes) considerably increases was revealed, at the beginning of sepsis. Existence of so operational method of diagnostics "on site" allows doctors not to overload an organism of the patient with "lethal" doses of antibiotics, building more sparing strategy of treatment. As, performing this diagnostics, requires microscopic amount of biomaterial, rapprochement of Lascco and Abionic looks quite logically. For the purpose of acceleration of rates of industrialization of this express diagnostics of Lascco initiated 8 parallel clinical trials for demonstration of efficiency of development. Now this diagnostic test begins to come to the market of Switzerland.

2007: Foundation of the company

In 2007 in the French high-speed train TGV (Train à Grande Vitesse) which was taking away spouses of Frédéric from Paris and Samareh Lajaunias they engendered the idea of an original method of a transfer of laboratory scientific developments in the field of biotechnologies in real industrial technologies and products for what they based own startup project of Lascco with two advanced developments.

At this time 28-year Samareh, was engaged in the doctoral dissertation about Parkinson's disease in research group of the president of the École polytechnique fédérale de Lausanne (EPFL) – professor of neurology and the head of laboratory of neurodegenerative diseases, Patrick Aebischer. At the same time 33-year Frédéric, having defended the dissertation at medical faculty of the University of Geneva, as well as more than 94 thousand his colleagues, continued to work in the European division of the American company Abbott Laboratories. But neither he nor it saw themselves in these "the big companies". Therefore, having armed with support and means of the families, friends and not indifferent experts, a couple of Lajaunias found Lascco to realize science.

In Switzerland very many mechanisms of support of entrepreneurs, in comparison with the number of mechanisms of support of a transfer of discoveries in specific products function. Having practical experience of work on both sides, Lajaunias accurately captured a key part of the problem of a transfer of laboratory developments to the real sector. The main problem consists in lack of desire of scientists to advance the opening in the industry on the one hand and the same unwillingness of industrial partners to buy the academic researches far from a practical stage of industrial samples. In it "a rupture of a chain" also the created Lascco should work. Which foundation was laid by 2 disruptive biotechnology projects: "Means of diagnosis of sepsis at seriously wounded of patients" and "Overcoming the stability of pathogenic bacteria developed to the existing antibiotics".